|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:activities
|
inhibits IL-23 signaling
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
Phase 2
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:first_described_by
|
gptkb:2015
|
|
gptkbp:formulation
|
liquid solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0699
|
|
gptkbp:indication
|
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
atopic dermatitis
|
|
gptkbp:ingredients
|
C23 H28 N4 O5 S
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of autoimmune diseases
|
|
gptkbp:manager
|
subcutaneous injection
|
|
gptkbp:related_to
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
psoriasis
|
|
gptkbp:research_areas
|
immunology
|
|
gptkbp:side_effect
|
headache
nausea
injection site reactions
|
|
gptkbp:sponsor
|
gptkb:Allergan_plc
|
|
gptkbp:status
|
investigational drug
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:IL-23
|
|
gptkbp:type_of
|
1234567-89-0
|
|
gptkbp:weight
|
460.56 g/mol
|